2023年2月第30卷第2期·论著·（临床研究）孟鲁司特钠联合沙美特罗替卡松对哮喘患者血清炎性因子水平及肺功能的影响赵玉仙，李震（南阳市第二人民医院呼吸内科，河南南阳473000）【摘要】目的探讨孟鲁司特钠联合沙美特罗替卡松对哮喘患者血清炎性因子水平及肺功能的影响。方法82例哮喘患者随机分为两组，对照组予以沙美特罗替卡松治疗，观察组在对照组基础上予以孟鲁司特钠治疗，比较两组的血清炎性因子水平、肺功能指标及不良反应。结果治疗后，观察组的IL-6、TNF-α、EOS水平均低于对照组，FVC、FEV1及PEF均高于对照组（P＜0.05）。两组的不良反应发生率比较，差异无统计学意义（P＞0.05）。结论孟鲁司特钠联合沙美特罗替卡松治疗哮喘可明显降低患者的炎性因子水平，促进患者肺功能恢复，且安全性较高。【关键词】哮喘；孟鲁司特钠；沙美特罗替卡松；炎性因子；肺功能中图分类号：R562.2+5文献标识码：Adoi:10.3969/j.issn.1674-4659.2023.02.0169ImpactofMontelukastSodiumCombinedwithSalmeterolFluticasoneonSerumInflammatoryFactorLevelsandLungFunctionofPatientswithAsthma//ZHAOYuxian,LIZhen(DepartmentofRespiratoryMedicine,NanyangSecondPeople'sHospital,Nanyang473000,China)[Abstract]ObjectiveToexploretheimpactofmontelukastsodiumcombinedwithsalmeterolfluticasoneonseruminflammatoryfactorlevelsandlungfunctionofpatientswithasthma.Methods82patientswithasthmawererandomlydividedintotwogroups.Thecontrolgroupwastreatedwithsalmeterolfluticasone,andtheobservationgroupwastreatedwithmontelukastsodiumonthebasisofthecontrolgroup.Thelevelsofseruminflammatoryfactors,lungfunctionindicatorsandadversereactionswerecomparedbetweenthetwogroups.ResultsAftertreatment,thelevelsofIL-6,TNF-αandEOSintheobservationgroupwerelowerthanthoseinthecontrolgroup,andFVC,FEV1andPEFwerehigherthanthoseinthecontrolgroup(P<0.05).Nostatisticaldifferencewasfoundintheincidenceofadversereactionsbetweenthetwogroups(P>0.05).ConclusionsMontelukastsodiumcombinedwithsalmeterolfluticasoneinthetreatmentofasthmacanobviouslyreducethelevelsofinflammatoryfactorsofpatients,promotetherecoveryoflungfunction,andhashighsafety.[Keywords]Asthma;Montelukastsodium;Salmeterolfluticasone;Inflammatoryfact...
